MedTrace Logo

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 521

Last updated 2017-05-10

No results posted yet for this study

Summary

This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.

Conditions

Interventions

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2590066A

Intramuscular injection, two doses

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2592984A

Intramuscular injection, two doses

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2340274A

Intramuscular injection, two doses

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2340273A

Intramuscular injection, two doses

OTHER

Placebo

Intramuscular injection, two doses

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-29
Primary Completion
2011-09-06
Completion
2012-08-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01236040 on ClinicalTrials.gov